Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04923113
Collaborator
(none)
200
1
16.5

Study Details

Study Description

Brief Summary

As we know,Helicobacter pylori is closely related to many gastrointestinal diseases such as chronic gastritis, peptic ulcer disease,gastric carcinoma and gastric mucosa-associated lymphoid tissue lymphoma,as well as extra-digestive diseases such as urticaria and chronic obstructive pulmonary diseases and so on.The diagnosis of H. pylori infection is based on invasive methods requiring endoscopy and biopsy(e.g. histology, culture, rapid urease test, PCR) or on non-invasive methods (e.g. serology, 13C urea breath test, stool antigen test).Histology has the highest specificity among the others,and also allows us to determine the underlying disease and perform antibiotic sensitivity testing.Serological tests are widely available and more appropriate for epidemiological studies, their main weakness for clinical use is low specificity.The 13C urea breath test is the most accurate method in patients irrespective of age.Stool antigen testing,as a promising method, is easy to perform, and its accuracy may be improved by the use of monoclonal antibodies recently proposed for capturing H. pylori antigen in stool specimen.Sensitivity and specificity, usefulness,and limitation of tests should be considered for selection of detection methods of H. pylori. Our objective is to review the current methods that are used for the detection of H. pylori infection among patients with chronic atrophic gastritis.Except that,patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Histology,13C urea breath test,Stool antigen test,Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori
  • Drug: Rabeprazole,Minocycline,Amoxicillin and Colloidal bismuth pectin
N/A

Detailed Description

Consecutive outpatients (18 to 70 years), with endoscopically proven chronic atrophic gastritis will be enrolled in our study.5 different methods,including histology,13C urea breath test,stool antigen test,serological antibody test for H.pylori and serologic test with a current infection marker of H.pylori,will be performed to detect H. pylori infection.And patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy.Our objective is to compare specificity and sensitivity of the current methods among patients with chronic atrophic gastritis,meanwhile,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis
Anticipated Study Start Date :
Jun 15, 2021
Anticipated Primary Completion Date :
Jun 15, 2022
Anticipated Study Completion Date :
Oct 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: patients who meet the inclusion criteria

5 different methods will be performed to detect H. pylori infection in patients who meet the inclusion criteria,and patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.

Diagnostic Test: Histology,13C urea breath test,Stool antigen test,Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori
The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection

Drug: Rabeprazole,Minocycline,Amoxicillin and Colloidal bismuth pectin
Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days

Outcome Measures

Primary Outcome Measures

  1. Sensitivity and specificity of different Helicobacter pylori detection methods [5 days]

    H.pylori infection status will be confirmed by 5 different methods,including histology,13C-UBT,stool antigen test,serological antibody test for H.pylori and serologic test with a current infection marker of H.pylori therapy.

Secondary Outcome Measures

  1. the efficacy of minocycline-based bismuth quadruple therapy for H.pylori eradication as a first-line therapy [5.5~13.5 weeks]

    patients with Hp positive(confirmed by either histology or13C-UBT) will be further treated with 10-day minocycline-based quadruple therapy.The eradication of H.pylori will be confirmed by negative 13C-or 14C-UBT 4~12 weeks after therapy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • participants was confirmed chronic atrophic gastritis by endoscopy

  • participants has not been previously received treatment for H.pylori infection.

Exclusion Criteria:
  • patients who were allergic to any study medications

  • patients who had taken antibiotics,bismuth agent,PPI or H2 receptor antagonist (H2RA) 4 weeks before the study

  • patients with previous gastrectomy

  • patients with malignancy or severe comorbidity

  • pregnant or lactating women

  • Patients with poor treatment compliance or could not express themselves correctly

  • patients who participated in other drug trial recently (within 3 months of enrollment).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

Investigators

  • Study Chair: Yue-Hua Han, PhD, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT04923113
Other Study ID Numbers:
  • 2021-0290
First Posted:
Jun 11, 2021
Last Update Posted:
Jun 11, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 11, 2021